{"entity":{"id":"newlink-genetics","kind":"company","name":"NewLink Genetics (now Lumos Pharma)","aka":["Lumos Pharma"],"tldr":"The Iowa biotech that ran the largest pancreatic cancer vaccine trial, IMPRESS, and the IDO inhibitor indoximod programme; it merged into Lumos Pharma in 2020.","summary":"NewLink Genetics developed the HyperAcute whole-cell vaccine platform, including algenpantucel-L for pancreatic cancer, and the IDO pathway inhibitor indoximod. After IMPRESS and PILLAR failed, the company merged with Lumos Pharma in 2020 and left oncology.","asOf":"2026-09-17","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/NewLink_Genetics"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["algenpantucel-l"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Ames, Iowa, United States","country":"US","companyType":"biotech","website":"https://www.lumos-pharma.com","founded":1999,"stage":"public","investors":[],"funding":[]},"route":"/companies/newlink-genetics/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"algenpantucel-l","kind":"drug","name":"Algenpantucel-L","route":"/drugs/algenpantucel-l/"}]}}